Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Makoto Ohori is active.

Publication


Featured researches published by Makoto Ohori.


Urology | 1999

Factors influencing morbidity in patients undergoing transurethral resection of the prostate

Toyoaki Uchida; Makoto Ohori; Shigehiro Soh; Takefumi Sato; Masatsugu Iwamura; Teruaki Ao; Ken Koshiba

OBJECTIVESnTransurethral resection of the prostate (TURP) has become the primary method to relieve bladder outlet obstruction for patients with benign prostatic hyperplasia (BPH). Data from 3861 consecutive patients with BPH who underwent TURP from 1971 to 1996 at our hospital were retrospectively analyzed.nnnMETHODSnThe patients were classified into two groups comprising 1930 patients who underwent TURP from 1971 to 1985 (early group) and 1931 patients who underwent TURP from 1985 to 1996 (late group). Risk factors associated with blood transfusions and perioperative complications were analyzed in these patients.nnnRESULTSnMortality, morbidity, and blood transfusions were noted in 5 (0.1 %), 516 (13.4%), and 507 (13.1%) patients, respectively. The blood transfusion and morbidity rates decreased over the 25-year period (P <0.001, chi-square test for trends), which was reflected in a decrease in these rates in the late group (6.1% and 9.5%, respectively) compared with those of the early group (20.2% and 17.2%, respectively). Postoperative bleeding and morbidity were closely related to prostatic gland size and operating time. The most significant differences for the risk of a blood transfusion were related to resection time, the amount of tissue resected, age, and the decade (1970s, 1980s, or 1990s) in which the surgery was performed (P <0.0005), whereas resection time was significantly correlated with morbidity (P <0.0005). As risk factors for each complication, the time of surgical resection, the decade of surgery, and the amount of tissue resected directly correlated with the incidence of extravasation and hemostatic procedures (P < or =0.003), whereas the incidence of postoperative epididymitis positively correlated with a preoperative vasectomy and a closed drainage system (P <0.0005).nnnCONCLUSIONSnSince the 1970s, the rates of blood transfusions and morbidity have decreased for patients undergoing TURP. Advances in techniques, instrumentation, and surgical and perioperative management, including anesthesia, have made TURP a relatively safe procedure, and it remains an effective means for treating patients with BPH.


The Journal of Urology | 1995

Does Transurethral Resection of the Prostate Pose a Risk to Life? 22-Year Outcome

Ken Koshiba; Shin Egawa; Makoto Ohori; Toyoaki Uchida; Eiji Yokoyama; Kiyoshi Shoji

The clinical outcomes of 717 patients who underwent transurethral resection for benign prostatic hyperplasia between 1971 and 1981, and of 48 who underwent open prostatectomy during the same period were evaluated. All living patients could be followed for a minimum of 12 years postoperatively. The cumulative percentage of patients undergoing a secondary operation was substantially greater after transurethral resection of the prostate than after open prostatectomy. The volume of resected tissue, operating time, requirement for blood transfusion and hyponatremia during or after the procedure did not affect long-term outcome of patients in the transurethral resection group. Abnormal preoperative electrocardiography and azotemia appeared to be associated with increased risk of postoperative mortality after controlling for other variables (p < 0.05). Actuarial survival rates did not differ substantially for patients who underwent transurethral resection and open prostatectomy, and exceeded the expected survival rates in the general male population in the same age group in Japan. Both procedures are safe for the symptomatic relief of urinary obstruction due to benign prostatic hyperplasia. Prostatectomy does not jeopardize long-term survival of the patients.


Cancer | 1995

Early detection of prostate cancer. Results of a prostate specific antigen‐based detection program in Japan

Shin Egawa; Kazuho Suyama; Makoto Ohori; Tatuhiro Kawakami; Sadahito Kuwao; Kazutaka Hirokado; Seiichiro Hirano; Eiji Yokoyama; Toyoaki Uchida; Ken Koshiba

Background. Prostate cancer increasingly is becoming a medical problem in Japan. To maximize the chance for cure, extensive effort is being made to detect prostate cancer while confined to the gland.


Cancer | 1997

The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan

Shin Egawa; Shigehiro Soh; Makoto Ohori; Toyoaki Uchida; Kazuo Gohji; Akio Fujii; Sadahito Kuwao; Ken Koshiba

To improve the clinical usefulness of prostate specific antigen (PSA), unique methods have been proposed. The percentage of free PSA in serum facilitates the distinction between benign histologic conditions and prostate carcinoma while retaining high sensitivity.


Cancer | 1997

Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.

Kazuo Gohji; Masashi Nomi; Shin Egawa; Koichi Morisue; Atsushi Takenaka; Masayuki Okamoto; Makoto Ohori; Akio Fujii

This study was undertaken to determine whether the prostate specific antigen (PSA) density (PSAD) and PSAD of the transition zone (PSADT) are useful in the detection of prostate carcinoma in Japanese men with intermediate levels of serum PSA.


Cancer | 1999

Parathyroid Hormone-Related Protein Is an Independent Prognostic Factor for Renal Cell Carcinoma

Masatsugu Iwamura; Weicheng Wu; Masatoshi Muramoto; Makoto Ohori; Shin Egawa; Toyoaki Uchida; Shiro Baba

Parathyroid hormone‐related protein (PTHrP) has been shown to be the principal cause of humoral hypercalcemia associated with renal cell carcinoma (RCC). Recent studies have demonstrated that the amino‐terminal region of PTHrP has growth factor‐like activities, suggesting it may play a role in the development of RCC. In this study, expression of the carboxy‐terminal region of PTHrP was assessed immunohistochemically and its significance in predicting the prognosis of RCC was studied.


International Journal of Urology | 1996

A Non‐Randomized Comparative Study of Visual laser Ablation and Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia

Toyoaki Uchida; Shin Egawa; Masatsugu Iwamura; Makoto Ohori; Eiji Yokoyama; Tadao Endo; Ken Koshiba

Background: Transurethral resection of the prustate (TURP) haz been the ‐preferred surgical treatment for benign prostatic hyperplasia (BPH) for the past 50 years. Alternative methods for treating BPH such as visual laser ablation (VLAP) have been established during the past decade. In order to assess the safety and efficacy of VLAP, this alternative method was performed using a Urolase fiber and neodymium: yttrium‐aluminum‐garnet laser and compared to results obtained in patients treated with TURP for BPH Methods: In this non‐randomized comparative study, 100 BPH patients were equally split between treatment with VLAP or TURP, and their cases compared. The efficacy was assessed using an International Prostate Symptom Score, urinary flow rates, post‐void residual urinary volume and an estimated prostate volume.


The Journal of Urology | 1996

Laparoscopically Assisted Heminephrectomy of a Horseshoe Kidney: A Case Report

Teruaki Ao; Toyoaki Uchida; Shin Egawa; Masatsugu Iwamura; Makoto Ohori; Ken Koshiba

Laparoscopic surgery is a minimally invasive alternative to an open While technically demanding, laparoscopic heminephrectomy may be the treatment of choice in certain cases. We report a case of laparoscopically assisted heminephrectomy for nonfunctioning giant hydronephrosis in a horseshoe kidney. CASE REPORT


International Journal of Urology | 1996

Visual laser Ablation of the Prostate and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia

Toyoaki Uchida; Makoto Ohori; Masatsugu Iwamura; Shin Egawa; Teruaki Ao; Eiji Yokoyama; Setsuo Mashimo; Tadao Endo; Ken Koshiba

For the past 50 years, transurethral resection of the prostate (TURP) has been the most common treatment for benign prostatic hyperplasia (BPH). The authors have conducted visual laser ablation of the prostate (VLAP) for BPH as a minimum invasive surgery. The results were compared with those of VLAP, VLAP+transurethral incision of the prostate (TUIP), and TURP as other treatments for BPH. In the VLAP group, 50 of 52 (96.2%), 36 of 40 (90.0%) and 31 of 36 (86.1%) were categorized as having more than a Fair Response (FR) at 3, 6 and 12 months, postoperatively. In the VLAP+TUIP group, 24 of 29 (82.8%), 19 of 22 (86.4%) and 9 of 11 (81.8%) were classed as having more than a FR at 3, 6 and 1 2 months, postoperatively. Forty–one of 42 (97.6%), 1 7 of 1 7 (100.0%) and 6 of 6 (100.0%) patients reaction to TURP was more than FR in overall response at 3, 6 and 12 months, postoperatively. The need for a blood transfusion, perforation of the prostate capsule and transit incontinence persisting for more than 1 month occurred in 1 of 45 (2.2%), 1 (2.2%) and 4 (8.9%) patients in the TURP group. Bladder neck contracture was seen in 4 of 52 (7.7%) in the VLAP group. Average postoperative catheter duration was shorter in the VLAP+TUIP (5.7 ± 8.4 days) than in the VLAP group (10.3 ± 10.4 days). Although TURP remains the standard treatment for BPH, VLAP results in less morbidity compared to TURP. VLAP with TUIP appears to lessen the risk of postoperative urinary retention and provide better results in longer follow–up studies.


Urologic Oncology-seminars and Original Investigations | 1998

The utility of free to total PSA ratio for detecting prostate cancer in Japanese men with total PSA between 2.1 and 10 ng/ml

Makoto Ohori; Shin Egawa; Ken Koshiba

We sought to determine whether the free to total prostate specific antigen (PSA) ratio in men with gray zone total PSA could accurately indicate the presence or absence of cancer, thus reducing the number of unnecessary biopsies without lessening the chance of detecting early stage prostate cancers. In 137 patients with total PSA levels between 2.1 and 10.0 ng/ml, we examined total PSA, free to total PSA ratio, PSA density (PSAD), and prostatic volume measured by transrectal ultrasound, and used these features to predict histologic features determined following sextant biopsy and/or surgery of the prostate. Of 137 patients with intermediate PSA levels, 25 (18%) had cancer. With a free to total PSA cut-off of 20%, cancer would not have been detected in 4 of the 25 patients (84% sensitivity), and 36% of the unnecessary negative biopsies would have been successfully avoided (p < 0.0005). With a PSAD cut-off of 0.15, cancer would have been missed in 4 of the 25 patients (84% sensitivity) and a 50% reduction in unnecessary negative biopsies would have been possible (p < 0.0005). Of 41 patients with large prostatic glands (>40 cm(3)), cancer was detected in only one, compared with 24 (25%) of 96 patients with small glands (<40 cm(3)) (p = 0.002). The results of receiver operating characteristic analysis indicated that PSAD, free to total PSA ratio, and prostatic volume would be effectively applicable to the diagnosis of cancer (areas under the curve: 0.7562, 0.7564, and 0.7693, respectively). At 100% sensitivity, specificity was highest for PSAD used in conjunction with ratio of free to total PSA. All patients with cancer had PSAD > 0.15 and/or free to total PSA < 15%. Patients with PSAD < 0.15 and free to total PSA ratio > 15% had no cancer (p < 0.0001). By this procedure, a 48% (54 of 112) reduction in the number of unnecessary biopsies would have been possible. Use of the free to total PSA ratio, measured with the AxSYM system, can significantly reduce unnecessary negative biopsies in patients with intermediate levels of PSA. Prostatic volume data can enhance the usefulness of this ratio for diagnosing prostate cancer.

Collaboration


Dive into the Makoto Ohori's collaboration.

Top Co-Authors

Avatar

Shin Egawa

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peter T. Scardino

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Thomas M. Wheeler

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge